Neurocrine to Acquire Soleno Therapeutics, Expanding Its Endocrinology and Rare Disease Portfolio - PR Newswire

Neurocrine to Acquire Soleno Therapeutics, Expanding Its Endocrinology and Rare Disease Portfolio  PR NewswireNeurocrine Biosciences to buy Soleno Therapeutics in $2.9B deal  AxiosNeurocrine expands into metabolic diseases with $2.9 billion Soleno buyout  CNBCNeurocrine, eying ‘blockbuster in the making,’ strikes its largest-ever M&A deal with $2.9B Soleno buyout  Fierce PharmaNeurocrine bets nearly $3bn on deal for insatiable hunger treatment  Financial Times